These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
173 related items for PubMed ID: 17280789
21. Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors? Oliver JJ. Int J Clin Pract; 2006 Sep; 60(9):1026-7. PubMed ID: 16939541 [No Abstract] [Full Text] [Related]
22. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3? Kass DA. Circulation; 2007 Jul 17; 116(3):233-5. PubMed ID: 17638937 [No Abstract] [Full Text] [Related]
34. Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much? Burnett AL. Eur Urol; 2006 Jul 17; 50(1):29-30. PubMed ID: 16567036 [No Abstract] [Full Text] [Related]
35. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. Rosen RC, Shaw JW. Int J Impot Res; 2006 Jul 17; 18(6):570-1; author reply 572-3. PubMed ID: 17075585 [No Abstract] [Full Text] [Related]
36. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. Hotston M, Shukla N, Bloor J, Persad R, Jeremy JY. BJU Int; 2006 Dec 17; 98(6):1331-2. PubMed ID: 17125493 [No Abstract] [Full Text] [Related]
37. Rationale for androgens and erectile dysfunction in 2006. Roumeguère T. Eur Urol; 2006 Nov 17; 50(5):898-900. PubMed ID: 16893603 [No Abstract] [Full Text] [Related]
38. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, Moens AL, Champion HC, Kass DA. Circulation; 2007 Apr 24; 115(16):2159-67. PubMed ID: 17420342 [Abstract] [Full Text] [Related]
39. PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension. Deibert P, Bremer H, Roessle M, Kurz-Schmieg AK, Kreisel W. Eur Respir J; 2007 Jan 24; 29(1):220-1. PubMed ID: 17197488 [No Abstract] [Full Text] [Related]
40. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors. Yoo J, Thai KM, Kim DK, Lee JY, Park HJ. Bioorg Med Chem Lett; 2007 Aug 01; 17(15):4271-4. PubMed ID: 17553682 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]